Widely used:Recently Viewed
Clear All
Value Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
₹22,835 Cr
--
5.2
45.66
0.36
-14.12 %
-2.15 %
0 %
270.49
-19.12
₹1,555.82 Cr
₹1,595.29 Cr
₹-2,347.35 Cr
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Wockhardt
| -0.87 | -8.27 | 27.90 | 217.92 | 52.84 | 41.06 | 3.97 |
|
BSE Healthcare
| -5.55 | -3.36 | -4.46 | 31.00 | 18.30 | 25.19 | 11.10 |
|
BSE Mid Cap
| -5.66 | -9.07 | -10.04 | 15.13 | 18.82 | 22.87 | 15.20 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Wockhardt
| 201.65 | 90.25 | -41.22 | -24.12 | 132.57 | -55.75 | -43.41 |
|
BSE Mid Cap
| 25.84 | 45.53 | 1.38 | 39.18 | 19.87 | -3.05 | -13.31 |
|
BSE Healthcare
| 43.09 | 36.97 | -12.10 | 20.87 | 61.45 | -3.55 | -5.89 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
--
--Min --Median --Max
--
--Min --Median --Max
--
Earnings Yield (%) = EBIT / Enterprise value
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | P/E Ratio | ROE |
|---|---|---|---|---|
| 1,468.10 | 41,436.51 | -- | -24.45 | |
| 567.80 | 30,632.24 | 233.66 | 3.18 | |
| 230.70 | 30,591.64 | 674.87 | 1.52 | |
| 819.55 | 32,989.92 | 68.46 | 10.65 |
Wockhardt Limited, a pharmaceutical and biotech company, manufactures and markets pharmaceuticals, medicinal, and chemical products in India, the United States, the United Kingdom, Switzerland, Ireland, Mexico, Russia, and internationally. It... develops various molecules primarily in the areas of infectious diseases, such as WCK 5222, WCK 4282, WCK 4873, WCK 771 and WCK 2349, and WCK 6777 molecules; and active pharmaceutical ingredients. The company's biopharmaceutical products include Glaritus, a long-acting biosimilar glargine; Wosulin, a recombinant human insulin; Wepox, an r-DNA erythropoietin; human insulin; and Biovac-B, a hepatitis B vaccine. Its pipeline also includes rapid and long-acting insulin analogues, concentrated insulins, GLP1 analogues, haemopoietins, biobetters and novel products, and delivery devices. In addition, the company provides contract manufacturing services. Wockhardt Limited was founded in 1967 and is headquartered in Mumbai, India. Read more
1999
Habil Khorakiwala
Murtaza Khorakiwala
Wockhardt
Chhatrapati Sambhajinagar - (Aurangabad), Maharashtra
Looking for more details about Wockhardt Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Wockhardt Ltd stood at ₹ 7,588 Cr as on 30-Sep-24
The share price of Wockhardt Ltd is ₹1,404.55 (NSE) and ₹1,405.45 (BSE) as of 17-Jan-2025 IST. Wockhardt Ltd has given a return of 52.84% in the last 3 years.
Wockhardt Ltd has a market capitalisation of ₹ 22,835 Cr as on 17-Jan-2025. As per Value Research classification, it is a Mid Cap company.
The P/B ratio of Wockhardt Ltd is 5.20 times as on 17-Jan-2025, a 27% premium to its peers’ median range of 4.09 times.
Since, TTM earnings of Wockhardt Ltd is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Wockhardt Ltd and enter the required number of quantities and click on buy to purchase the shares of Wockhardt Ltd.
Wockhardt Limited, a pharmaceutical and biotech company, manufactures and markets pharmaceuticals, medicinal, and chemical products in India, the United States, the United Kingdom, Switzerland, Ireland, Mexico, Russia, and internationally. It develops various molecules primarily in the areas of infectious diseases, such as WCK 5222, WCK 4282, WCK 4873, WCK 771 and WCK 2349, and WCK 6777 molecules; and active pharmaceutical ingredients. The company's biopharmaceutical products include Glaritus, a long-acting biosimilar glargine; Wosulin, a recombinant human insulin; Wepox, an r-DNA erythropoietin; human insulin; and Biovac-B, a hepatitis B vaccine. Its pipeline also includes rapid and long-acting insulin analogues, concentrated insulins, GLP1 analogues, haemopoietins, biobetters and novel products, and delivery devices. In addition, the company provides contract manufacturing services. Wockhardt Limited was founded in 1967 and is headquartered in Mumbai, India.
The prominent promoters of Wockhardt Ltd. are
| Name of promoters | Holding percentage |
|---|---|
|
Themisto Trustee Company Private Limited |
40.16%
|
|
Pasithee Trustee Company Private Limited |
2.72%
|
|
Ananke Trustee Company Private Limited |
2.35%
|
|
Callirhoe Trustee Company Private Limited |
1.92%
|
The chairman of the company is Habil Khorakiwala, and the managing director is Murtaza Khorakiwala.
The promoters of Wockhardt Ltd have pledged 8.34% of the total equity as on Dec-24.
Some of the close peers are:
| Company | Market Cap(₹ Cr) |
|---|---|
|
41,437
|
|
|
32,990
|
|
|
30,632
|
|
|
30,592
|
| Wockhardt Ltd. | Ratios |
|---|---|
|
Return on equity(%)
|
-8.53
|
|
Operating margin(%)
|
-2.95
|
|
Net Margin(%)
|
-9.67
|
|
Dividend yield(%)
|
0
|
No, TTM profit after tax of Wockhardt Ltd was ₹-288 Cr.
₹36.30
(
